Toll Free: 1-888-928-9744

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 63 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2016', provides an overview of the Secondary (Hypogonadotropic) Hypogonadism pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Secondary (Hypogonadotropic) Hypogonadism
- The report reviews pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Secondary (Hypogonadotropic) Hypogonadism therapeutics and enlists all their major and minor projects
- The report assesses Secondary (Hypogonadotropic) Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Secondary (Hypogonadotropic) Hypogonadism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Secondary (Hypogonadotropic) Hypogonadism Overview 6 Therapeutics Development 7 Pipeline Products for Secondary (Hypogonadotropic) Hypogonadism - Overview 7 Pipeline Products for Secondary (Hypogonadotropic) Hypogonadism - Comparative Analysis 8 Secondary (Hypogonadotropic) Hypogonadism - Therapeutics under Development by Companies 9 Secondary (Hypogonadotropic) Hypogonadism - Therapeutics under Investigation by Universities/Institutes 10 Secondary (Hypogonadotropic) Hypogonadism - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Secondary (Hypogonadotropic) Hypogonadism - Products under Development by Companies 13 Secondary (Hypogonadotropic) Hypogonadism - Products under Investigation by Universities/Institutes 14 Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development 15 Forendo Pharma Limited 15 Merck & Co., Inc. 16 Mereo Biopharma Group Limited 17 Millennium Pharmaceuticals, Inc. 18 Repros Therapeutics Inc. 19 Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 BGS-649 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 corifollitropin alfa - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 enclomiphene citrate - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 fispemifene - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Kisspeptin-10 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 MSS-722 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 TAK-448 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 testosterone undecanoate - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Secondary (Hypogonadotropic) Hypogonadism - Recent Pipeline Updates 40 Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects 55 Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products 56 Secondary (Hypogonadotropic) Hypogonadism - Product Development Milestones 57 Featured News & Press Releases 57 Mar 28, 2016: Apricus Reports Top-Line Phase 2b Data for Fispemifene in Symptomatic Secondary Hypogonadism 57 Mar 15, 2016: Repros Announces Initiation of Formal Approval Process by the European Medicines Agency 57 Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men 58 Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism 59 Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference and Provide Update on Fispemifene 59 Jan 11, 2016: Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company 59 Jan 04, 2016: Repros Updates Enclomiphene Program 60 Dec 01, 2015: Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene 60 Dec 01, 2015: Apricus Biosciences Confirms Clinical Strategy for Its Novel Treatment for Symptomatic Secondary Hypogonadism Fispemifene 60 Oct 29, 2015: Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables
Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2016 7 Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Forendo Pharma Limited, H1 2016 15 Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co., Inc., H1 2016 16 Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Limited, H1 2016 17 Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 18 Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Repros Therapeutics Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Secondary (Hypogonadotropic) Hypogonadism Therapeutics - Recent Pipeline Updates, H1 2016 40 Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, H1 2016 55 Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, H1 2016 56


List of Figures
Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2016 7 Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 12 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Targets, H1 2016 21 Number of Products by Stage and Targets, H1 2016 21 Number of Products by Mechanism of Actions, H1 2016 23 Number of Products by Stage and Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27 Number of Products by Stage and Molecule Types, H1 2016 27

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...

Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3D

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify